Tevogen Bio Inc. (TVGN)
0.99
-0.02 (-1.98%)
At close: Apr 25, 2025, 3:59 PM
0.97
-1.81%
Pre-market: Apr 28, 2025, 04:22 AM EDT
Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
The company is based in Warren, New Jersey.
Tevogen Bio Inc.
| Country | United States |
| IPO Date | Jan 5, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. |
Contact Details
Address: 15 Independence Blvd Warren, New Jersey United States | |
| Website | https://tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| CUSIP Number | 88165K101 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer & Chairperson |
| Kirti Desai CPA | Chief Financial Officer |
| Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
| David E. Banko CPA | Global Head of Government Affairs & Patient Access |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
| Sadiq Khan M.B.A. | Chief Commercial Officer |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Tapan V. Shah | Head of Investor Relations & Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 02, 2025 | 10-K | Annual Report |
| Apr 01, 2025 | NT 10-K | Filing |
| Mar 14, 2025 | 4 | Filing |
| Mar 11, 2025 | 4 | Filing |
| Mar 06, 2025 | 4 | Filing |
| Jan 28, 2025 | 424B3 | Filing |
| Jan 28, 2025 | 8-K | Current Report |